Asthma in the real world - 27/06/13
Doi : 10.1016/j.jaci.2013.03.052
Paul M. O'Byrne, MB, FRCP(C) ⁎ 
Firestone Institute for Respiratory Health, St Joseph’s Healthcare, and the Department of Medicine, McMaster University, Hamilton, Ontario, Canada
∗Corresponding author: Paul M. O'Byrne, MB, FRCP(C), HSC 3W10, McMaster University, 1200 Main St W, Hamilton, Ontario L8N 3Z5, Canada.
Key words : Adherence, inhaled corticosteroids, long-acting inhaled β-agonists, leukotriene receptor antagonists
Le texte complet de cet article est disponible en PDF.
| Disclosure of potential conflict of interest: P. M. O'Byrne has been supported by one or more grants from AIM, AstraZeneca, Amgen, GlaxoSmithKline, ONO, Genentech, and Novartis; has received one or more consulting fees or honoraria from AstraZeneca, GlaxoSmithKline, Merck, and Novartis; and has received one or more fees for participation from the Joint Oversight Board for LABA safety study. |
© 2013
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 132 - N° 1
P. 70-71 - juillet 2013 Retour au numéro
Article précédent
- Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthmatic subjects
- Annette T. Hastie, Wendy C. Moore, Huashi Li, Brian M. Rector, Victor E. Ortega, Rodolfo M. Pascual, Stephen P. Peters, Deborah A. Meyers, Eugene R. Bleecker, National Heart, Lung, and Blood Institute's Severe Asthma Research Program
- What is an “eosinophilic phenotype” of asthma?
- Parameswaran Nair
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?